178 filings
8-K
ICPT
Intercept Pharmaceuticals, Inc.
8 Nov 23
Entry into a Material Definitive Agreement
4:44pm
8-K
ICPT
Intercept Pharmaceuticals, Inc.
26 Sep 23
Entry into a Material Definitive Agreement
8:28am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
2 Aug 23
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:05am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
23 Jun 23
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
6:35am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
22 Jun 23
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
8:50pm
8-K
iyzkg mpykb8v
25 May 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
j80mktke
19 May 23
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
7:27pm
8-K
xl7 m8cdnxzc6
17 May 23
Entry into a Material Definitive Agreement
5:43pm
8-K
zcx64 0dkcwzq93r
27 Apr 23
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
7:05am
8-K
10eor6r30c e1ji
24 Mar 23
Entry into a Material Definitive Agreement
5:18pm
8-K
2pamp1n
2 Mar 23
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
7:05am
8-K
52g6cyp4 zrpe
27 Feb 23
Other Events
8:00am
8-K
jfz sf9dmxixtljlpy
21 Feb 23
Other Events
8:00am
8-K
nrbjv p28er
2 Feb 23
Departure of Directors or Certain Officers
5:15pm
8-K
08pvrgsl42 lo
25 Jan 23
Other Events
8:00am
8-K
6lgcwg6k
19 Jan 23
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
8:05am
8-K
1il48ek72qx38j
17 Jan 23
Other Events
8:00am
8-K
qhmxqnu39jhasqyi0ft9
11 Jan 23
Regulation FD Disclosure
8:00am
8-K
e39mxj1gf0ch19g2c
23 Dec 22
Regulation FD Disclosure
8:00am
8-K
es8frqr66 eda
1 Nov 22
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
7:05am